The role of azacitidine in the management of myelodysplastic syndromes (MDS)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

KS G&ouml;tze, C M&uuml;ller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universit&auml;t M&uuml;nchen, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders characterized by ineffective hemat...

Full description

Bibliographic Details
Main Authors:	KS G&ouml;tze, C M&uuml;ller-Thomas, C Peschel
Format:	Article
Language:	English
Published:	Dove Medical Press 2009-10-01
Series:	Cancer Management and Research
Online Access:	http://www.dovepress.com/the-role-of-azacitidine-in-the-management-of-myelodysplastic-syndromes-a3618

Similar Items

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
by: Daisuke Okamura, et al.
Published: (2014-01-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
by: Chen, J, et al.
Published: (2022)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)
by: J. Y. Chen, et al.
Published: (2022-06-01)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
by: Sallman, D, et al.
Published: (2022)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
by: N. Rajakumaraswamy, et al.
Published: (2022-06-01)

Trisomy X and myelodysplastic syndrome (MDS) with eosinophilia
by: Mohd Tohit, Eusni Rahayu, et al.
Published: (2012)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
by: Annika Kasprzak, et al.
Published: (2022-04-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
by: D. A. Sallman, et al.
Published: (2022-06-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
by: Henrik Hasle, et al.
Published: (2023-12-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
by: Konstantinos Liapis, et al.
Published: (2021-02-01)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
by: Xiaoqing Xie, et al.
Published: (2021-12-01)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

The Role of Hepcidin in Myelodysplastic Syndromes (MDS): A Systematic Review of Observational Studies
by: Artur Słomka, et al.
Published: (2024-01-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
by: I. Mandac Smoljanovic, et al.
Published: (2024-01-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
by: Sabine Blum, et al.
Published: (2021-09-01)

The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
by: Oriol Calvete, et al.
Published: (2023-02-01)

P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
by: K. Hasegawa, et al.
Published: (2022-06-01)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
by: Ai Yoshioka, et al.
Published: (2017-11-01)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

Levodopa/carbidopa and entacapone in the treatment of Parkinson&rsquo;s disease: efficacy, safety and patient preference
by: Thomas M&uuml;ller
Published: (2009-01-01)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
by: Unnikrishnan, A, et al.
Published: (2017)

Adults Myelodysplastic Syndromes in Algeria: A Study by the Algerian MDS Group
by: Mohamed Amine Bekadja, et al.
Published: (2023-04-01)

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
by: Ashwin Unnikrishnan, et al.
Published: (2017-07-01)

Qualitative flow cytometric analysis of Malaysian myelodysplastic syndromes (MDS) patients.
by: Broojerdi, Mohadese Hashem, et al.
Published: (2012)

Current State and Challenges in Development of Targeted Therapies in Myelodysplastic Syndromes (MDS)
by: Michele Stanchina, et al.
Published: (2021-04-01)

Microvesicles/exosomes as potential novel biomarkers of metabolic diseases
by: M&uuml;ller G
Published: (2012-08-01)